NCT05894694View on ClinicalTrials.gov

Survival Benefit of Compound Kushen Injection in the Treatment of Advanced Colorectal Cancer

PHASE4RecruitingINTERVENTIONAL
Enrollment

320

Participants

Timeline

Start Date

September 27, 2023

Primary Completion Date

December 30, 2025

Study Completion Date

December 31, 2025

Conditions
Advanced Colorectal Carcinoma
Interventions
DRUG

first-line scheme+compound kushen injection

FOLFOX/FOLFIRI/CAPEOX± Cetuximab/bevacizumab+compound kushen injection Compound Kushen injection: intravenous infusion, 20ml at a time, diluted with 200ml sodium chloride injection, once a day, each cycle of chemotherapy should reach the cumulative dose of 200ml.

DRUG

palliative care group first-line scheme

FOLFOX/FOLFIRI/CAPEOX± Cetuximab/bevacizumab

Trial Locations (1)

Unknown

RECRUITING

Guang 'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing

All Listed Sponsors
lead

Guang'anmen Hospital of China Academy of Chinese Medical Sciences

OTHER